BeiGene, Ltd. – NASDAQ:BGNE
Founder-led company
BeiGene, Ltd. stock price today
$184.71
+2.82
+1.55%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
BeiGene, Ltd. stock price monthly change
+19.53%
month
BeiGene, Ltd. stock price quarterly change
+19.53%
quarter
BeiGene, Ltd. stock price yearly change
+1.65%
year
BeiGene, Ltd. key metrics
Market Cap | 19.85B |
Enterprise value | 22.87B |
P/E | -13.22 |
EV/Sales | 16.15 |
EV/EBITDA | -12.41 |
Price/Sales | 18.46 |
Price/Book | 5.96 |
PEG ratio | 0.48 |
EPS | -6.96 |
Revenue | 2.76B |
EBITDA | -1.05B |
Income | -784.42M |
Revenue Q/Q | 67.85% |
Revenue Y/Y | 77.42% |
Profit margin | -141.86% |
Oper. margin | -126.4% |
Gross margin | -36.09% |
EBIT margin | -126.4% |
EBITDA margin | -38.07% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBeiGene, Ltd. stock price history
BeiGene, Ltd. stock forecast
BeiGene, Ltd. financial statements
Average Price Target
$267.33
Potential upside: 44.73%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 595.26M | -381.13M | -64.03% |
|---|---|---|---|
| Sep 2023 | 781.30M | 215.41M | 27.57% |
| Dec 2023 | 634.40M | -367.55M | -57.94% |
| Mar 2024 | 751.65M | -251.15M | -33.41% |
| 2022-11-09 | -5.39 | -5.39 |
|---|---|---|
| 2022-12-31 | -2.35967 | -4.29186 |
| 2023-02-28 | -4.42213 | -4.29 |
| Jun 2023 | 5728736000 | 1.93B | 33.69% |
|---|---|---|---|
| Sep 2023 | 5524879000 | 1.76B | 31.89% |
| Dec 2023 | 5805275000 | 2.23B | 38.48% |
| Mar 2024 | 5667681000 | 2.27B | 40.13% |
| Jun 2023 | -293.88M | 67.8M | 166.08M |
|---|---|---|---|
| Sep 2023 | -78.15M | -186.27M | -76.78M |
| Dec 2023 | -221.63M | -62.58M | 347.04M |
| Mar 2024 | -308.57M | -209.83M | 162.29M |
BeiGene, Ltd. alternative data
| Aug 2023 | 9,400 |
|---|---|
| Sep 2023 | 10,000 |
| Oct 2023 | 10,000 |
| Nov 2023 | 10,000 |
| Dec 2023 | 10,000 |
| Jan 2024 | 10,000 |
| Feb 2024 | 10,000 |
| Mar 2024 | 10,600 |
| Apr 2024 | 10,600 |
| May 2024 | 10,600 |
| Jun 2024 | 10,000 |
| Jul 2024 | 10,000 |
BeiGene, Ltd. other data
1.04%
-2.63%
of BGNE is owned by hedge funds
136
-69
13.95M
-35.42M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 397 |
| Mar 2024 | 0 | 50000 |
| Apr 2024 | 0 | 50000 |
| Jun 2024 | 0 | 14442 |
| Jul 2024 | 0 | 1306 |
| Sep 2024 | 0 | 16895 |
| Oct 2024 | 0 | 15279 |
| Nov 2024 | 0 | 48351 |
| Dec 2024 | 0 | 18921277 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | OYLER JOHN director, officer.. | Share Option (Right to Buy) | 1,300,000 | $0.5 | $650,000 | ||
Option | OYLER JOHN director, officer.. | Ordinary Shares | 1,300,000 | $0.5 | $650,000 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 1,300 | $188.79 | $245,428 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 1,833 | $190.57 | $349,311 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 993 | $191.78 | $190,435 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 1,374 | $192.61 | $264,642 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 725 | $194.01 | $140,655 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 300 | $195.67 | $58,700 | ||
Option | WANG XIAODONG director, other: .. | American Depositary Shares | 41,760 | $6.5 | $271,440 | ||
Sale | WANG XIAODONG director, other: .. | American Depositary Shares | 2,600 | $183.6 | $477,368 |
| Patent |
|---|
Application DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE Filling date: 24 Jul 2020 Issue date: 8 Sep 2022 |
Application Filling date: 17 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 3 Jul 2020 Issue date: 25 Aug 2022 |
Application Filling date: 24 Jul 2020 Issue date: 11 Aug 2022 |
Application Filling date: 29 May 2020 Issue date: 28 Jul 2022 |
Application Filling date: 21 May 2020 Issue date: 21 Jul 2022 |
Grant Filling date: 13 Jul 2021 Issue date: 19 Jul 2022 |
Grant Filling date: 12 Aug 2018 Issue date: 5 Jul 2022 |
Application Filling date: 24 Nov 2021 Issue date: 19 May 2022 |
Application Filling date: 15 Nov 2021 Issue date: 5 May 2022 |
| Quarter | Transcript |
|---|---|
| Q4 2018 28 Feb 2019 | Q4 2018 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Xiaodong Wang Ph.D. (1963) Co-Founder, Chairman of the Scientific Advisory Board & Non-Executive Director | $4,250,000 |
| Mr. John V. Oyler (1968) Co-Founder, Executive Chairman & Chief Executive Officer | $1,410,000 |
| Dr. Xiaobin Wu Ph.D. (1962) Pres, Chief Operating Officer & GM of China | $1,230,000 |
Dr. Edna Huang M.D. (1973) Chief Medical Officer of Hematology | $749,550 |
BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)
Week In Review: Hengrui And Dearon Announce $7.2B In Drug Licensings
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Updated View On Jazz Pharmaceuticals' 2025 Goals
BeiGene: Debating On Finally Establishing A Position
Nurix Therapeutics: A Unique Approach To BTK Targeting
Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch
-
What's the price of BeiGene, Ltd. stock today?
One share of BeiGene, Ltd. stock can currently be purchased for approximately $184.71.
-
When is BeiGene, Ltd.'s next earnings date?
Unfortunately, BeiGene, Ltd.'s (BGNE) next earnings date is currently unknown.
-
Does BeiGene, Ltd. pay dividends?
No, BeiGene, Ltd. does not pay dividends.
-
How much money does BeiGene, Ltd. make?
BeiGene, Ltd. has a market capitalization of 19.85B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 73.65% to 2.46B US dollars. BeiGene, Ltd. made a loss 881.71M US dollars in net income (profit) last year or -$4.29 on an earnings per share basis.
-
What is BeiGene, Ltd.'s stock symbol?
BeiGene, Ltd. is traded on the NASDAQ under the ticker symbol "BGNE".
-
What is BeiGene, Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BeiGene, Ltd.?
Shares of BeiGene, Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BeiGene, Ltd.'s key executives?
BeiGene, Ltd.'s management team includes the following people:
- Dr. Xiaodong Wang Ph.D. Co-Founder, Chairman of the Scientific Advisory Board & Non-Executive Director(age: 62, pay: $4,250,000)
- Mr. John V. Oyler Co-Founder, Executive Chairman & Chief Executive Officer(age: 57, pay: $1,410,000)
- Dr. Xiaobin Wu Ph.D. Pres, Chief Operating Officer & GM of China(age: 63, pay: $1,230,000)
- Dr. Edna Huang M.D. Chief Medical Officer of Hematology(age: 52, pay: $749,550)
-
Is BeiGene, Ltd. founder-led company?
Yes, BeiGene, Ltd. is a company led by its founders Dr. Xiaodong Wang Ph.D. and Mr. John V. Oyler.
-
How many employees does BeiGene, Ltd. have?
As Jul 2024, BeiGene, Ltd. employs 10,000 workers, which is 6% less then previous quarter.
-
When BeiGene, Ltd. went public?
BeiGene, Ltd. is publicly traded company for more then 9 years since IPO on 3 Feb 2016.
-
What is BeiGene, Ltd.'s official website?
The official website for BeiGene, Ltd. is beigene.com.
-
Where are BeiGene, Ltd.'s headquarters?
BeiGene, Ltd. is headquartered at 55 Cambridge Parkway, Cambridge, MA.
-
How can i contact BeiGene, Ltd.?
BeiGene, Ltd.'s mailing address is 55 Cambridge Parkway, Cambridge, MA and company can be reached via phone at +7 818011800.
-
What is BeiGene, Ltd. stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for BeiGene, Ltd. in the last 12 months, the avarage price target is $267.33. The average price target represents a 44.73% change from the last price of $184.71.
BeiGene, Ltd. company profile:
BeiGene, Ltd.
beigene.comExchange:
NASDAQ
Full time employees:
10,600
Industry:
Biotechnology
Sector:
Healthcare
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
55 Cambridge Parkway
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001651308
ISIN: US07725L1026
CUSIP: 07725L102
